SAB Biotherapeutics to Present at INNODIA Annual Meeting
MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024.
- MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced their Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA will share an overview of the SAB-142 clinical development plan and anticipated milestones at the INNODIA Annual Meeting in Leuven, Belgium on April 11, 2024.
- SAB will be featured as a key partner at the upcoming global T1D meeting.
- INNODIA Managing Director Manuela Battaglia, Ph.D, said of the partnership, “SAB-142 is an exciting therapy in development, and we are optimistic about partnership opportunities for upcoming clinical trials with this novel agent.
- Our partnership will provide SAB – as with all our partners – access to our network of clinical trial sites and T1D experts as we work together to accelerate this important therapy.”
“INNODIA has been an exceptional partner as we move our SAB-142 development plan forward,” noted Dr. Kropotova.